Kane Biotech Statistics
Total Valuation
Kane Biotech has a market cap or net worth of 7.33 million. The enterprise value is 8.49 million.
| Market Cap | 7.33M |
| Enterprise Value | 8.49M |
Important Dates
The last earnings date was Thursday, May 22, 2025.
| Earnings Date | May 22, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 165.87M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +24.10% |
| Shares Change (QoQ) | +9.04% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 99.80M |
Valuation Ratios
The trailing PE ratio is 1.68.
| PE Ratio | 1.68 |
| Forward PE | n/a |
| PS Ratio | 4.31 |
| PB Ratio | -9.29 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 1.94 |
| EV / Sales | 4.72 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -2.86 |
Financial Position
The company has a current ratio of 0.56
| Current Ratio | 0.56 |
| Quick Ratio | 0.30 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.48 |
| Interest Coverage | -12.88 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -53.93% |
| Return on Invested Capital (ROIC) | -767.00% |
| Return on Capital Employed (ROCE) | -810.81% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.57 |
| Inventory Turnover | 7.83 |
Taxes
| Income Tax | -911,578 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -60.80% in the last 52 weeks. The beta is 0.18, so Kane Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.18 |
| 52-Week Price Change | -60.80% |
| 50-Day Moving Average | 0.05 |
| 200-Day Moving Average | 0.07 |
| Relative Strength Index (RSI) | 55.26 |
| Average Volume (20 Days) | 13,868 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Kane Biotech had revenue of 1.70 million and earned 4.37 million in profits. Earnings per share was 0.03.
| Revenue | 1.70M |
| Gross Profit | 608,406 |
| Operating Income | -2.57M |
| Pretax Income | -2.92M |
| Net Income | 4.37M |
| EBITDA | -2.53M |
| EBIT | -2.57M |
| Earnings Per Share (EPS) | 0.03 |
Balance Sheet
The company has 343,399 in cash and 1.44 million in debt, giving a net cash position of -1.09 million.
| Cash & Cash Equivalents | 343,399 |
| Total Debt | 1.44M |
| Net Cash | -1.09M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -788,965 |
| Book Value Per Share | -0.01 |
| Working Capital | -699,553 |
Cash Flow
In the last 12 months, operating cash flow was -2.94 million and capital expenditures -23,259, giving a free cash flow of -2.97 million.
| Operating Cash Flow | -2.94M |
| Capital Expenditures | -23,259 |
| Free Cash Flow | -2.97M |
| FCF Per Share | n/a |
Margins
Gross margin is 35.82%, with operating and profit margins of -151.16% and 257.02%.
| Gross Margin | 35.82% |
| Operating Margin | -151.16% |
| Pretax Margin | -171.86% |
| Profit Margin | 257.02% |
| EBITDA Margin | -148.75% |
| EBIT Margin | -151.16% |
| FCF Margin | n/a |
Dividends & Yields
Kane Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -24.10% |
| Shareholder Yield | n/a |
| Earnings Yield | 59.58% |
| FCF Yield | -40.48% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on March 13, 2017. It was a reverse split with a ratio of 0.2.
| Last Split Date | Mar 13, 2017 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
Kane Biotech has an Altman Z-Score of -19.45 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -19.45 |
| Piotroski F-Score | 4 |